Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
- DOI
- 10.1016/j.jaad.2018.01.016
- Published
- 2018 May
- Container
- Journal of the American Academy of Dermatology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jaad.2018.01.016,
title = {Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.},
author = {Guttman-Yassky E and Brunner PM and Neumann AU and Khattri S and Pavel AB and Malik K and Singer GK and Baum D and Gilleaudeau P and Sullivan-Whalen M and Rose S and Jim On S and Li X and Fuentes-Duculan J and Estrada Y and Garcet S and Traidl-Hoffmann C and Krueger JG and Lebwohl MG},
year = {2018},
journal = {Journal of the American Academy of Dermatology},
doi = {10.1016/j.jaad.2018.01.016},
url = {https://doi.org/10.1016/j.jaad.2018.01.016}
}RIS
TY - JOUR TI - Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. AU - Guttman-Yassky E AU - Brunner PM AU - Neumann AU AU - Khattri S AU - Pavel AB AU - Malik K AU - Singer GK AU - Baum D AU - Gilleaudeau P AU - Sullivan-Whalen M AU - Rose S AU - Jim On S AU - Li X AU - Fuentes-Duculan J AU - Estrada Y AU - Garcet S AU - Traidl-Hoffmann C AU - Krueger JG AU - Lebwohl MG PY - 2018 JO - Journal of the American Academy of Dermatology DO - 10.1016/j.jaad.2018.01.016 UR - https://doi.org/10.1016/j.jaad.2018.01.016 ER -
APA
E, G., PM, B., AU, N., S, K., AB, P., K, M., GK, S., D, B., P, G., M, S., S, R., S, J. O., X, L., J, F., Y, E., S, G., C, T., JG, K., & MG, L. (2018). Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2018.01.016
Source records
- pubmed · retrieved 2026-09-26T19:09:36.166Z